Matches in SemOpenAlex for { <https://semopenalex.org/work/W2789853461> ?p ?o ?g. }
Showing items 1 to 81 of
81
with 100 items per page.
- W2789853461 endingPage "180" @default.
- W2789853461 startingPage "180" @default.
- W2789853461 abstract "180 Background: Anti-PD-1 therapy is effective in many cancers, but tumor-intrinsic factors governing response and resistance are largely unknown. MHC-II (HLA-DR) expression on tumor cells can predict response to anti-PD-1. Thus, we sought to determine the molecular features of MHC-II+ tumors in the evolution of anti-PD-1 response. Methods: We performed RNA-seq on 58 anti-PD-1 treated melanoma and lung tumors, including a subset of matched specimens prior to treatment and at acquired resistance. We performed immunohistochemistry (IHC) for immunologic markers, including HLA-DR on tumor cells. In triple-negative breast cancers (TNBC; n = 103), we performed IHC and/or quantitative immunofluorescence (QIF) for LAG3, PD-L1, CD4, CD8, Fc-receptor-like 6 (FCRL6), and granzyme B (GZMB). QIF images were assessed by Automated Quantitative Analysis (AQUA). To determine the functional effect of MHC-II on tumor cells, we generated isogenic MHC-II+ mouse tumors and assessed immune responsiveness and efficacy of checkpoint inhibition. Results: We identified unique inflammatory signatures in HLA-DR+ tumors, correlating with enhanced pre-treatment CD4+ and CD8+ tumor-infiltrating lymphocytes (TILs) and response to anti-PD-1. LAG3+ and FCRL6+ TILs were enriched in HLA-DR+ tumors. LAG3 and FCRL6, known inhibitory receptors which bind MHC-II, were elevated at anti-PD-1 resistance. Similarly, in > 100 TNBCs, HLA-DR+ tumor cells associated with increased CD4+ and CD8+ TILs and enhanced LAG3+ and FCRL6+ TILs. Further, presence of MHC-II-suppressing (LAG3+/FCRL6+) TILs associated with decreased GZMB+ CD8+ T cells, suggesting suppressed cytotoxicity. In mice, enforced expression of MHC-II on tumor cells enhanced CD4-enhanced anti-tumor immunity but was thwarted by LAG3+ TIL recruitment. Combined anti-LAG3 and anti-PD-1 therapy was selectively effective in MHC-II+ tumors. Conclusions: MHC-II+ tumors are immunologically active and may circumvent anti-tumor immunity by targeting MHC-II antigen presentation via recruitment of MHC-II-suppressing TILs. MHC-II expression may be useful to stratify patients to anti-PD-1/anti-LAG3 and eventually, anti-PD-1/anti-FCRL6 combinations." @default.
- W2789853461 created "2018-03-29" @default.
- W2789853461 creator A5006434494 @default.
- W2789853461 creator A5012147802 @default.
- W2789853461 creator A5016015665 @default.
- W2789853461 creator A5017831693 @default.
- W2789853461 creator A5025067315 @default.
- W2789853461 creator A5027474910 @default.
- W2789853461 creator A5033580931 @default.
- W2789853461 creator A5037252693 @default.
- W2789853461 creator A5051194540 @default.
- W2789853461 creator A5055450312 @default.
- W2789853461 creator A5056593501 @default.
- W2789853461 creator A5089113899 @default.
- W2789853461 date "2018-02-10" @default.
- W2789853461 modified "2023-10-14" @default.
- W2789853461 title "MHC-II expression to drive a unique pattern of adaptive resistance to antitumor immunity through receptor checkpoint engagement." @default.
- W2789853461 doi "https://doi.org/10.1200/jco.2018.36.5_suppl.180" @default.
- W2789853461 hasPublicationYear "2018" @default.
- W2789853461 type Work @default.
- W2789853461 sameAs 2789853461 @default.
- W2789853461 citedByCount "8" @default.
- W2789853461 countsByYear W27898534612018 @default.
- W2789853461 countsByYear W27898534612019 @default.
- W2789853461 countsByYear W27898534612020 @default.
- W2789853461 countsByYear W27898534612021 @default.
- W2789853461 countsByYear W27898534612022 @default.
- W2789853461 crossrefType "journal-article" @default.
- W2789853461 hasAuthorship W2789853461A5006434494 @default.
- W2789853461 hasAuthorship W2789853461A5012147802 @default.
- W2789853461 hasAuthorship W2789853461A5016015665 @default.
- W2789853461 hasAuthorship W2789853461A5017831693 @default.
- W2789853461 hasAuthorship W2789853461A5025067315 @default.
- W2789853461 hasAuthorship W2789853461A5027474910 @default.
- W2789853461 hasAuthorship W2789853461A5033580931 @default.
- W2789853461 hasAuthorship W2789853461A5037252693 @default.
- W2789853461 hasAuthorship W2789853461A5051194540 @default.
- W2789853461 hasAuthorship W2789853461A5055450312 @default.
- W2789853461 hasAuthorship W2789853461A5056593501 @default.
- W2789853461 hasAuthorship W2789853461A5089113899 @default.
- W2789853461 hasConcept C167672396 @default.
- W2789853461 hasConcept C170627219 @default.
- W2789853461 hasConcept C203014093 @default.
- W2789853461 hasConcept C2777701055 @default.
- W2789853461 hasConcept C2778326572 @default.
- W2789853461 hasConcept C2780380082 @default.
- W2789853461 hasConcept C2780851360 @default.
- W2789853461 hasConcept C502942594 @default.
- W2789853461 hasConcept C71924100 @default.
- W2789853461 hasConcept C8891405 @default.
- W2789853461 hasConceptScore W2789853461C167672396 @default.
- W2789853461 hasConceptScore W2789853461C170627219 @default.
- W2789853461 hasConceptScore W2789853461C203014093 @default.
- W2789853461 hasConceptScore W2789853461C2777701055 @default.
- W2789853461 hasConceptScore W2789853461C2778326572 @default.
- W2789853461 hasConceptScore W2789853461C2780380082 @default.
- W2789853461 hasConceptScore W2789853461C2780851360 @default.
- W2789853461 hasConceptScore W2789853461C502942594 @default.
- W2789853461 hasConceptScore W2789853461C71924100 @default.
- W2789853461 hasConceptScore W2789853461C8891405 @default.
- W2789853461 hasIssue "5_suppl" @default.
- W2789853461 hasLocation W27898534611 @default.
- W2789853461 hasOpenAccess W2789853461 @default.
- W2789853461 hasPrimaryLocation W27898534611 @default.
- W2789853461 hasRelatedWork W2057768232 @default.
- W2789853461 hasRelatedWork W2154497454 @default.
- W2789853461 hasRelatedWork W2789853461 @default.
- W2789853461 hasRelatedWork W2886882409 @default.
- W2789853461 hasRelatedWork W2898908382 @default.
- W2789853461 hasRelatedWork W2908970744 @default.
- W2789853461 hasRelatedWork W2955876518 @default.
- W2789853461 hasRelatedWork W3195957488 @default.
- W2789853461 hasRelatedWork W4230847397 @default.
- W2789853461 hasRelatedWork W4291378227 @default.
- W2789853461 hasVolume "36" @default.
- W2789853461 isParatext "false" @default.
- W2789853461 isRetracted "false" @default.
- W2789853461 magId "2789853461" @default.
- W2789853461 workType "article" @default.